MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) — TVM Capital Life Science (“TVM”), a top international venture capital firm focused on investments in life sciences innovation, nowadays announced that Dr. Luc Marengère, Managing Companion, and Dr. Sascha Berger, Basic Companion of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings with each other top innovators, active investors and committed strategics from the medtech industry to companion and create subsequent-generation healthcare technologies. The conference will take location March 20-23, 2023, in Dana Point, California, USA.

“Medtech innovation plays a pivotal part in the healthcare ecosystem and has the prospective to revolutionize the business by enhancing patient outcomes, escalating efficiency, and lowering expenses. 1 important element of our tactic is to invest in disruptive, breakthrough, industrial-stage technologies that map important future trends and considerably transform existing normal-of-care. In addition to connecting with fellow investors and dealmakers to go over market place possibilities and desires, we appear forward to meeting young, hugely revolutionary organizations at the LSI Summit to additional expand TVM’s robust medtech portfolio,” mentioned Dr. Luc Marengère.

TVM pursues a one of a kind two-pronged tactic, investing in differentiated health-related technologies with industrial proof-of-idea and late clinical-stage therapeutics as effectively as financing revolutionary early-stage therapeutics by means of a single asset corporation strategy (Project-Focused Organization, PFC) that leverages TVM’s strategic connection with international pharmaceutical firm, Eli Lilly and Organization. With its late-stage medtech investments, the Organization focuses on revolutionary corporations from North America or the EU functioning to transform health-related practice with their groundbreaking devices and technologies.

Dr. Sascha Berger added: “TVM’s track record of thriving collaboration highlights our partnership and worth-creating strategy with innovators. As accurate partners, we operate closely with our portfolio organizations, striving to comprehend their suggestions, and locate approaches to advance their innovations to accelerate development, facilitate market place expansion and in the end enable them grow to be or continue to be a leader in their respective markets. With our existing fund TVM Life Science Innovation II, we continue to expand our tactic, that has been validated by means of a quantity of organizations in each Fund I and II, to create a portfolio of differentiated items with robust leadership teams.”

Investment highlights from TVM’s medtech industrial-stage portfolio contain:

• Access Vascular Inc. has created and commercializes award-winning intravenous catheters addressing the most popular and pricey complications of intravenous therapy: infection, thrombosis, and phlebitis. Engineered to mimic the body’s organic chemistry, Access Vascular catheters are made to evade foreign physique response and associated complications.
• Egg Healthcare has created and commercializes a lab radiation protection program that considerably reduces scatter radiation exposure throughout interventional angiographic procedures. During an X-ray, radiation reflects off a patient and scatters to any individual else in the space. This benefits in an improved danger of cancer chromosomal abnormalities, skin harm and eye injury for healthcare experts in this field. EGGNEST™ reduces scatter radiation exposure by 91% for the whole group without the need of interrupting the workflow.
• Emovi’s technologies and AI options address clinical challenges that exist by means of the continuum of care for sufferers with knee discomfort and pathology. The Organization has created the only FDA cleared, Wellness Canada licensed and CE Marked health-related device to assess the 3D motion of the knee and comprehend what is taking place in patient’s knee in order to superior determine causes of symptoms and propose a thriving care program.
• Kent Imaging, a top innovator in close to-infrared tissue oxygenation imaging, develops, manufactures, and markets health-related technologies that supports genuine-time choice-producing in wound care, vascular and surgical subspecialties and tracks the healing procedure. Kent Imaging targets limb preservation and reconstructive surgical markets – places with clear unmet have to have, as non-healing wounds are a important burden to sufferers and the healthcare program.
• Panthera Dental, a planet leader in CAD/CAM implant options and dental sleep appliances, has effectively combined creativity, science and know-how to bring to market place its proprietary revolutionary technologies to offer you subsequent-generation items to the dental business as effectively as a novel innovation to treat sleep apnea. The Organization just not too long ago launched a new solution: The Magnet-XTM, the world’s initial removable magnetic implant bar providing steady forces, lateral guidance and stability and effortless handling for sufferers with much less dexterity.

About TVM Capital Life Science
TVM Capital Life Science (“TVM”) is a top international venture capital firm focused on investing in life science innovations. The Organization has a hugely skilled transatlantic investment group and about $900 million beneath management. TVM’s portfolio focuses on therapeutics and health-related technologies from North America and the EU that represent differentiated initial-in-class or finest-in-class assets with the prospective to transform normal of care.

TVM pursues a one of a kind two-pronged tactic, financing revolutionary early-stage therapeutics by means of a single asset corporation strategy (Project-Focused Organization, PFC) that leverages the firm’s strategic connection with international pharmaceutical firm, Eli Lilly and Organization. TVM also invests in differentiated industrial-stage health-related technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated health-related technologies with industrial proof-of-idea as effectively as late-stage therapeutics anticipated to rapidly attain important improvement or regulatory milestones. This tactic has been validated by means of a quantity of organizations in each Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment group has worked with each other for more than a decade to properly use this revolutionary strategy to maximize returns for investors and finance new therapies and technologies to meaningfully boost patient lives.

Media Relations

MC Solutions AG

Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
E mail: tvm@mc-solutions.eu